Burgdorf and Eindhoven (NL), 04.10.2018, 7.00 a.m. – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite Digital Platform. The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on Philips HealthSuite Digital Platform. The combination of Ypsomed connected self-medication devices with Philips’ HealthSuite Digital Platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes.

Ypsomed expands to more countries with its YpsoPump insulin pump

Press Releases Ypsomed Group

Burgdorf – Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin pump therapy.

Press Releases Ypsomed Group

Burgdorf – Ypsomed has collaborated with Biocon, an emerging global biopharmaceutical company headquartered in India, to customise its reusable YpsoPen for use with Biocon’s insulin cartridges. This customised reusable pen will be marketed by Biocon as INSUPen Pro™ in Malaysia.

Ypsomed opens a new production line in Solothurn

Press Releases Ypsomed Group

Burgdorf – Following 18 months of industrialisation, Ypsomed opened its new production line in their Solothurn works and will have created over 50 new jobs on final expansion. The inauguration was held yesterday with representatives of local commerce and guests from politics in attendance.